ADAM9 promotes lung cancer metastases to brain by a plasminogen activator-based pathway

Cancer Research

Volumn 74, Issue 18, 2014, Pages 5229-5243

  Lin, Chen Yuan ^a,b   Chen, Hung Jen ^b   Huang, Cheng Chung ^b   Lai, Liang Chuan ^c   Lu, Tzu Pin ^c   Tseng, Guan Chin ^b   Kuo, Ting Ting ^b   Kuok, Qian Yu ^b   Hsu, Jennifer L ^b,d,e   Sung, Shian Ying ^f   Hung, Mien Chie ^a,b,d,e   Sher, Yuh Pyng ^a,b  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^d UNIVERSITY OF TEXAS   (United States)

^e ASIA UNIVERSITY   (Taiwan)

^f TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ADAM PROTEIN; ADAM9 PROTEIN, HUMAN; CDCP1 PROTEIN, HUMAN; CELL ADHESION MOLECULE; DASATINIB; DEXAMETHASONE; LEUKOCYTE ANTIGEN; MEMBRANE PROTEIN; PLASMINOGEN ACTIVATOR; PYRIMIDINE DERIVATIVE; THIAZOLE DERIVATIVE; TUMOR PROTEIN;

ADENOCARCINOMA; ANIMAL; BRAIN NEOPLASMS; DEFICIENCY; DISEASE MODEL; GENE SILENCING; GENETICS; HUMAN; LUNG NEOPLASMS; METABOLISM; METASTASIS; MOUSE; PATHOLOGY; SCID MOUSE; SECONDARY; TUMOR CELL LINE; XENOGRAFT;

ADAM PROTEINS; ADENOCARCINOMA; ANIMALS; ANTIGENS, CD; BRAIN NEOPLASMS; CELL ADHESION MOLECULES; CELL LINE, TUMOR; DEXAMETHASONE; DISEASE MODELS, ANIMAL; GENE KNOCKDOWN TECHNIQUES; HETEROGRAFTS; HUMANS; LUNG NEOPLASMS; MEMBRANE PROTEINS; MICE; MICE, SCID; NEOPLASM METASTASIS; NEOPLASM PROTEINS; PLASMINOGEN ACTIVATORS; PYRIMIDINES; THIAZOLES;

EID: 84907486062     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-2995     Document Type: Article

References (47)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30.
2. Gavrilovic IT, Posner JB. Brain metastases: epidemiology and pathophysiology. J Neurooncol 2005;75:5-14.
3. Schwer AL, Gaspar LE. Update in the treatment of brain metastases from lung cancer. Clin Lung Cancer 2006;8:180-6.
4. Kienast Y, von Baumgarten L, Fuhrmann M, Klinkert WE, Goldbrunner R, Herms J, et al. Real-time imaging reveals the single steps of brain metastasis formation. Nat Med 2010;16:116-22.
5. Grinberg-Rashi H, Ofek E, Perelman M, Skarda J, Yaron P, Hajduch M, et al. The expression of three genes in primary non-small cell lung cancer is associated with metastatic spread to the brain. Clin Cancer Res 2009;15:1755-61.
6. Shintani Y, Higashiyama S, Ohta M, Hirabayashi H, Yamamoto S, Yoshimasu T, et al. Overexpression of ADAM9 in non-small cell lung cancer correlates with brain metastasis. Cancer Res 2004;64:4190-6.
7. Wolfsberg TG, Primakoff P, Myles DG, White JM. ADAM, a novel family of membrane proteins containing a disintegrin and metalloprotease domain: multipotential functions in cell-cell and cell-matrix interactions. J Cell Biol 1995;131:275-8.
8. Nath D, Slocombe PM, Webster A, Stephens PE, Docherty AJ, Murphy G. Meltrin γ (ADAM-9) mediates cellular adhesion through α (6) β (1) integrin, leading to a marked induction of fibroblast cell motility. J Cell Sci 2000;113(Pt 12):2319-28.
9. Iba K, Albrechtsen R, Gilpin BJ, Loechel F, Wewer UM. Cysteine-rich domain of human ADAM 12 (meltrin α) supports tumor cell adhesion. Am J Pathol 1999;154:1489-501.
10. Guaiquil V, Swendeman S, Yoshida T, Chavala S, Campochiaro PA, Blobel CP. ADAM9 is involved in pathological retinal neovascularization. Mol Cell Biol 2009;29:2694-703.
11. Grutzmann R, Luttges J, Sipos B, Ammerpohl O, Dobrowolski F, Alldinger I, et al. ADAM9 expression in pancreatic cancer is associated with tumour type and is a prognostic factor in ductal adenocarcinoma. Br J Cancer 2004;90:1053-8.
12. O'Shea C, McKie N, Buggy Y, Duggan C, Hill AD, McDermott E, et al. Expression of ADAM-9 mRNA and protein in human breast cancer. Int J Cancer 2003;105:754-61.
13. Sung SY, Kubo H, Shigemura K, Arnold RS, Logani S, Wang R, et al. Oxidative stress induces ADAM9 protein expression in human prostate cancer cells. Cancer Res 2006;66:9519-26.
14. Chu YW, Yang PC, Yang SC, Shyu YC, Hendrix MJ, Wu R, et al. Selection of invasive and metastatic subpopulations from a human lung adenocarcinoma cell line. Am J Respir Cell Mol Biol 1997;17:353-60.
15. Sher YP, Tzeng TF, Kan SF, Hsu J, Xie X, Han Z, et al. Cancer targeted gene therapy of BikDD inhibits orthotopic lung cancer growth and improves long-term survival. Oncogene 2009;28:3286-95.
16. Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 2002;30:207-10.
17. Lee ES, Son DS, Kim SH, Lee J, Jo J, Han J, et al. Prediction of recurrence-free survival in postoperative non-small cell lung cancer patients by using an integrated model of clinical information and gene expression. Clin Cancer Res 2008;14:7397-404.
18. Matsuyama Y, Suzuki M, Arima C, Huang QM, Tomida S, Takeuchi T, et al. Proteasomal non-catalytic subunit PSMD2 as a potential therapeutic target in association with various clinicopathologic features in lung adenocarcinomas. Mol Carcinog 2011;50:301-9.
19. Director's Challenge Consortium for the Molecular Classification of Lung A, Shedden K, Taylor JM, Enkemann SA, Tsao MS, Yeatman TJ, et al. Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med 2008;14:822-7.
20. Lu TP, Lai LC, Tsai MH, Chen PC, Hsu CP, Lee JM, et al. Integrated analyses of copy number variations and gene expression in lung adenocarcinoma. PLoS ONE 2011;6:e24829.
21. Lu TP, Tsai MH, Lee JM, Hsu CP, Chen PC, Lin CW, et al. Identification of a novel biomarker, SEMA5A, for non-small cell lung carcinoma in nonsmoking women. Cancer Epidemiol Biomarkers Prev 2010;19:2590-7.
22. Mehta MP, Paleologos NA, Mikkelsen T, Robinson PD, Ammirati M, Andrews DW, et al. The role of chemotherapy in the management of newly diagnosed brain metastases: a systematic review and evidencebased clinical practice guideline. J Neurooncol 2010;96:71-83.
23. Cruz-Munoz W, Kerbel RS. Preclinical approaches to study the biology and treatment of brain metastases. Semin Cancer Biol 2011;21:123-30.
24. Palmieri D, Bronder JL, Herring JM, Yoneda T, Weil RJ, Stark AM, et al. Her-2 overexpression increases the metastatic outgrowth of breast cancer cells in the brain. Cancer Res 2007;67:4190-8.
25. Uekita T, Jia L, Narisawa-Saito M, Yokota J, Kiyono T, Sakai R. CUB domain-containing protein 1 is a novel regulator of anoikis resistance in lung adenocarcinoma. Mol Cell Biol 2007;27:7649-60.
26. Hooper JD, Zijlstra A, Aimes RT, Liang H, Claassen GF, Tarin D, et al. Subtractive immunization using highly metastatic human tumor cells identifies SIMA135/CDCP1, a 135 kDa cell surface phosphorylated glycoprotein antigen. Oncogene 2003;22:1783-94.
27. Deryugina EI, Conn EM, Wortmann A, Partridge JJ, Kupriyanova TA, Ardi VC, et al. Functional role of cell surface CUB domain-containing protein 1 in tumor cell dissemination. Mol Cancer Res 2009;7:1197-211.
28. Bhatt AS, Erdjument-Bromage H, Tempst P, Craik CS, Moasser MM. Adhesion signaling by a novel mitotic substrate of src kinases. Oncogene 2005;24:5333-43.
29. Casar B, He Y, Iconomou M, Hooper JD, Quigley JP, Deryugina EI. Blocking of CDCP1 cleavage in vivo prevents Akt-dependent survival and inhibits metastatic colonization through PARP1-mediated apoptosis of cancer cells. Oncogene 2012;31:3924-38.
30. He Y, Wortmann A, Burke LJ, Reid JC, Adams MN, Abdul-Jabbar I, et al. Proteolysis-induced N-terminal ectodomain shedding of the integral membrane glycoprotein CUB domain-containing protein 1 (CDCP1) is accompanied by tyrosine phosphorylation of its C-terminal domain and recruitment of Src and PKCδ. J Biol Chem 2010;285:26162-73.
31. Niego B, Freeman R, Puschmann TB, Turnley AM, Medcalf RL. t-PA-specific modulation of a human blood-brain barrier model involves plasmin-mediated activation of the Rho kinase pathway in astrocytes. Blood 2012;119:4752-61.
32. Yepes M, Sandkvist M, Moore EG, Bugge TH, Strickland DK, Lawrence DA. Tissue-type plasminogen activator induces opening of the bloodbrain barrier via the LDL receptor-related protein. J Clin Invest 2003;112:1533-40.
33. Law ME, Corsino PE, Jahn SC, Davis BJ, Chen S, Patel B, et al. Glucocorticoids and histone deacetylase inhibitors cooperate to block the invasiveness of basal-like breast cancer cells through novel mechanisms. Oncogene 2013;32:1316-29.
34. Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, Behnia K, et al. Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl) - piperazin-1-yl)-2-methylpyrimidin-4-ylamino) thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004;47:6658-61.
35. Buettner R, Mesa T, Vultur A, Lee F, Jove R. Inhibition of Src family kinases with dasatinib blocks migration and invasion of human melanoma cells. Mol Cancer Res 2008;6:1766-74.
36. Saftig P, Reiss K. The "A Disintegrin And Metalloproteases" ADAM10 and ADAM17: novel drug targets with therapeutic potential? Eur J Cell Biol 2011;90:527-35.
37. Kalyan NK, Lee SG, Wilhelm J, Fu KP, Hum WT, Rappaport R, et al. Structure-function analysis with tissue-type plasminogen activator. Effect of deletion of NH2-terminal domains on its biochemical and biological properties. J Biol Chem 1988;263:3971-8.
38. Ito Y, Takeda T, Higashiyama S, Sakon M, Wakasa KI, Tsujimoto M, et al. Expression of heparin binding epidermal growth factor-like growth factor in hepatocellular carcinoma: an immunohistochemical study. Oncol Rep 2001;8:903-7.
39. Ray KC, Moss ME, Franklin JL, Weaver CJ, Higginbotham J, Song Y, et al. Heparin-binding epidermal growth factor-like growth factor eliminates constraints on activated Kras to promote rapid onset of pancreatic neoplasia. Oncogene 2014;33:823-31.
40. Fischer OM, Hart S, Gschwind A, Prenzel N, Ullrich A. Oxidative and osmotic stress signaling in tumor cells is mediated by ADAM proteases and heparin-binding epidermal growth factor. Mol Cell Biol 2004;24:5172-83.
41. Dong Y, He Y, de Boer L, Stack MS, Lumley JW, Clements JA, et al. The cell surface glycoprotein CUB domain-containing protein 1 (CDCP1) contributes to epidermal growth factor receptor-mediated cell migration. J Biol Chem 2012;287:9792-803.
42. Medcalf RL, Schleuning WD. Regulation of human tissue-type plasminogen activator gene transcription by epidermal growth factor and 30, 50-cyclic adenosine monophosphate. Mol Endocrinol 1991;5:1773-9.
43. Paugh BS, Paugh SW, Bryan L, Kapitonov D, Wilczynska KM, Gopalan SM, et al. EGF regulates plasminogen activator inhibitor-1 (PAI-1) by a pathway involving c-Src, PKCδ, and sphingosine kinase 1 in glioblastoma cells. FASEB J 2008;22:455-65.
44. Liao H, Hyman MC, Lawrence DA, Pinsky DJ. Molecular regulation of the PAI-1 gene by hypoxia: contributions of Egr-1, HIF-1α, and C/EBPα. FASEB J 2007;21:935-49.
45. de Witte JH, Sweep CG, Klijn JG, Grebenschikov N, Peters HA, Look MP, et al. Prognostic value of tissue-type plasminogen activator (tPA) and its complex with the type-1 inhibitor (PAI-1) in breast cancer. Br J Cancer 1999;80:286-94.
46. Borgfeldt C, Bendahl PO, Ferno M, Casslen B. High preoperative plasma concentration of tissue plasminogen activator (tPA) is an independent marker for shorter overall survival in patients with ovarian cancer. Gynecol Oncol 2003;91:112-7.
47. Janicke F, Schmitt M, Graeff H. Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer. Semin Thromb Hemost 1991;17:303-12.